Literature DB >> 17416736

NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.

Vasiliki Leventaki1, Elias Drakos, L Jeffrey Medeiros, Megan S Lim, Kojo S Elenitoba-Johnson, Francois X Claret, George Z Rassidakis.   

Abstract

Anaplastic large-cell lymphoma (ALCL) frequently carries the t(2;5)(p23;q35), resulting in aberrant expression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). We show that in 293T and Jurkat cells, forced expression of active NPM-ALK, but not kinase-dead mutant NPM-ALK (210K>R), induced JNK and cJun phosphorylation, and this was linked to a dramatic increase in AP-1 transcriptional activity. Conversely, inhibition of ALK activity in NPM-ALK(+) ALCL cells resulted in a concentration-dependent dephosphorylation of JNK and cJun and decreased AP-1 DNA-binding. In addition, JNK physically binds NPM-ALK and is highly activated in cultured and primary NPM-ALK(+) ALCL cells. cJun phosphorylation in NPM-ALK(+) ALCL cells is mediated by JNKs, as shown by selective knocking down of JNK1 and JNK2 genes using siRNA. Inhibition of JNK activity using SP600125 decreased cJun phosphorylation and AP-1 transcriptional activity and this was associated with decreased cell proliferation and G2/M cell-cycle arrest in a dose-dependent manner. Silencing of the cJun gene by siRNA led to a decreased S-phase cell-cycle fraction associated with upregulation of p21 and downregulation of cyclin D3 and cyclin A. Taken together, these findings reveal a novel function of NPM-ALK, phosphorylation and activation of JNK and cJun, which may contribute to uncontrolled cell-cycle progression and oncogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17416736     DOI: 10.1182/blood-2006-11-059451

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 2.  Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place.

Authors:  Panagiotis Kotsantis; Eva Petermann; Simon J Boulton
Journal:  Cancer Discov       Date:  2018-04-13       Impact factor: 39.397

Review 3.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

4.  Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.

Authors:  Fang Wu; Peng Wang; Jingdong Zhang; Leah C Young; Raymond Lai; Liang Li
Journal:  Mol Cell Proteomics       Date:  2010-04-14       Impact factor: 5.911

5.  Induced ATF-2 represses CDK4 transcription through dimerization with JunD inhibiting intestinal epithelial cell growth after polyamine depletion.

Authors:  Lan Xiao; Jaladanki N Rao; Tongtong Zou; Lan Liu; Ting-Xi Yu; Xiao-Yu Zhu; James M Donahue; Jian-Ying Wang
Journal:  Am J Physiol Cell Physiol       Date:  2010-02-24       Impact factor: 4.249

Review 6.  CARMA1-mediated NF-kappaB and JNK activation in lymphocytes.

Authors:  Marzenna Blonska; Xin Lin
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry.

Authors:  Peng Wang; Fang Wu; Yupo Ma; Liang Li; Raymond Lai; Leah C Young
Journal:  J Biol Chem       Date:  2009-11-02       Impact factor: 5.157

Review 8.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

9.  JNK1/2 expression and modulation of STAT3 signaling in oral cancer.

Authors:  Ioannis Gkouveris; Nikolaos Nikitakis; Maria Karanikou; George Rassidakis; Alexandra Sklavounou
Journal:  Oncol Lett       Date:  2016-05-24       Impact factor: 2.967

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.